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Prior to the release of the initial ﬁndings of the
Multicenter Selective Lymphadenectomy Trial-1
(MSLT-1), SLN biopsy had already been generally
embraced by the worldwide surgical community as a
valuable staging tool and as a minimally invasive way
to accurately identify patients with clinically occult
regional lymph node metastases. The application of
regional lymph node dissection only for patients with
positive SLNs–termed ‘‘selective lymphadenec-
tomy’’–effectively minimizes the development of
clinical nodal disease and spares node-negative pa-
tients the morbidity of a formal lymph node dissec-
tion. This management strategy has been promoted
as a rational alternative to the two prior popularized
approaches of elective lymph node dissection
(ELND) or nodal observation. At the same time, a
relatively vocal minority argued that a survival
advantage from SLN biopsy should be demonstrated
before the routine use of this procedure was en-
dorsed.
In the fall of 2006, the highly anticipated results of
the third of ﬁve planned interim analyses of the
MSLT-1 were published.
1 This trial was undertaken
to compare the outcomes of patients with newly
diagnosed primary cutaneous melanoma treated with
either WLE plus observation of the regional nodes
followed by regional lymphadenectomy if nodal
metastases became clinically apparent (the observa-
tion group) or WLE plus SLN biopsy (the SLN
group) and (1) immediate regional lymphadenectomy
if a SLN was positive (ie, selective lymphadenectomy)
or (2) observation if the SLN was negative. The pri-
mary goal was to assess the survival impact of SLN
biopsy; the trial also addressed several other ques-
tions regarding the use of SLN biopsy in the initial
management of patients with melanoma.
This interim analysis of the MSLT-1
1 conﬁrms
previous reports that SLN status is the most powerful
independent predictor of survival, but does not pro-
vide a deﬁnitive answer on whether SLN biopsy
provides a survival advantage. With a median follow-
up of 5 years, this analysis showed a 3%, non-sig-
niﬁcant survival advantage for patients in the SLN
biopsy group. Careful consideration of the trial data
suggests that this lack of overall survival beneﬁt from
SLN biopsy is not surprising. In order to fully
understand the results of this interim MSLT-1 anal-
ysis, reﬂection upon previous randomized ELND
trials is instructive.
A signiﬁcant body of evidence now exists related to
the survival impact of treating microscopic nodal
disease in patients with melanoma. In two random-
ized trials in melanoma patients at high risk for
clinically occult nodal disease,
2,3 ELND was com-
pared with nodal observation followed by delayed
lymph node dissection if palpable nodal disease
developed. In both trials, there was a trend toward
improved survival in the ELND group, but this was
not signiﬁcant. Critics concluded from these trials
that early treatment of nodal metastases has little
impact on disease progression. However, others
suggested that because only the 20% of patients who
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670harbored clinically occult nodal disease could
potentially beneﬁt from ELND, the trials were
underpowered to detect a survival difference. In
contrast, analyses limited to patients with nodal dis-
ease have shown a survival beneﬁt from early lymph
node dissection. The post-hoc analysis of the World
Health Organization truncal melanoma randomized
ELND trial showed a signiﬁcantly higher 5-year
survival rate for patients with microscopically posi-
tive lymph nodes who underwent ELND at the time
of wide local excision (WLE) than for those who
underwent delayed lymph node dissection after
developing clinical disease (48% vs. 27%, P = .04).
3
The results of a multi-center retrospective trial from
Germany revealed that completion lymph node dis-
section following a positive SLN biopsy improved
survival compared with delayed dissection of clini-
cally apparent lymph node metastases (63% versus
50% at 5-years).
4 These data call into question the
practice of delaying lymphadenectomy until palpable
disease develops in patients with clinically negative
lymph nodes.
Similar trial design limitations exist in MSLT-1.
First, only 19% of the patients in the SLN group (i.e.,
those with a positive SLN at the time of biopsy) could
potentially beneﬁt from early therapeutic lymph node
dissection. If one assumes, based on observations
from the aforementioned trials, that approximately
15%–20% of the microscopic node positive patients
actually benefit from an early dissection, a survival
advantage of no more than 3% - 4% (i.e., 15–20% of
19%) would be expected for the overall SLN biopsy
group compared to the overall observation group.
The trial did not have sufficient power to detect such
a survival benefit. However, the two above-noted
ELND trials showed that with increasing follow-up,
survival differences increased as more events occurred
in the observation group than in the immediate
ELND group.
2,3 It therefore seems appropriate to
speculate that greater survival differences may
emerge with longer follow-up of the MSLT-1.
An additional planned analysis from the MSLT-1
trial compared the patients who had positive SLNs
and underwent immediate lymphadenectomy versus
the patients in the observation group who later
developed palpable nodal disease. The results from
this secondary analysis are particularly noteworthy:
there was a signiﬁcant progression to more advanced
nodal disease in the nodal observation group, and
there was a signiﬁcant survival advantage (20%) for
the SLN-positive patients who underwent immediate
lymphadenectomy. These data corroborate the earlier
ﬁndings from the World Health Organization and
German studies described above and demonstrate
that left intact, micrometastases can grow and be
associated with a worse prognosis.
3,4 Such increased
nodal burden may also represent a source of distant
dissemination. Thus, this secondary analysis shows
that early treatment of nodal disease can favorably
alter the natural history of melanoma.
Opponents of the SLN approach have criticized
this subset analysis and maintain that this survival
comparison is invalid because the patients were not
randomly assigned to these subgroups and the
underlying biology of patients with microscopic
lymph node involvement may not necessarily be the
same as for patients who developed palpable nodal
disease. Others have suggested that the reason for the
improved survival observed in the SLN-positive
group is that the small volume of disease identiﬁed in
some of the patients was clinically irrelevant—i.e.,
that this nodal disease would never have progressed
and that the positive SLNs in these patients should be
considered ‘‘falsely positive.’’ Recently, a review
5 and
accompanying editorial
6—both focusing on the
MSLT-1—were published in Nature Clinical Practice
Oncology. These articles suggested that survival dif-
ferences thus far observed among the various node-
positive groups in the MSLT-1 could be explained by
differences in their constellation of prognostic fac-
tors.
While such criticisms should be considered, it is
also logical to conclude, based on the MSLT-1 data,
that the patients in the two subgroups were similar
and that the microscopic metastases in SLNs would
most likely have progressed to palpable disease if left
intact, for the following ﬁve reasons. (1) Since this
was a well-designed and appropriately stratiﬁed
prospective randomized trial, the incidence of
microscopic nodal disease in the two treatment
groups should have been identical. (2) The percentage
of SLN-group patients with nodal disease (discovered
at SLN biopsy or as false-negative events during
subsequent follow-up and observation) is nearly
identical to the percentage of observation-group pa-
tients who have thus far developed palpable nodal
disease and is predicted to be identical by 10 years of
follow-up (Fig. 1)
7 (3)The mean number of positive
nodes was 1.6 in the SLN-positive group, 3.6 in the
nodal observation group, and 4.3 in the false-negative
SLN group, (ie, greater tumor burden in the two
patients groups in whom regional disease was not
removed early). (4) If a signiﬁcant proportion of the
positive SLNs were not clinically relevant, the rate of
false-negative ﬁndings of SLN biopsy would have
been higher. (5) The assertion that the node-positive
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SLN biopsy, or false-negative SLN biopsy—are
prognostically different is unfounded and erroneous.
As reported in the MSLT-1 study, the median pri-
mary tumor thickness and ulceration status of these
groups were essentially the same and not statistically
different.
1 Therefore, the most likely—and arguably
the simplest—explanation for the observed survival
differences between these node-positive groups is that
removal of positive SLNs followed by completion
lymph node dissection minimized the progression of
nodal disease and the associated increased risk of
distant dissemination. Longer follow-up of these pa-
tients is warranted to determine if over time the
incidence of palpable nodal recurrence among pa-
tients randomized to nodal observation will continue
to be higher than the incidence of additional false-
negative events in the SLN-negative group. If these
future events follow the patterns observed in the two
aforementioned ELND trials,
2,3 there might be more
recurrences in the nodal observation arm over time
than in the SLN biopsy arm.
An additional argument promulgated against the
routine use of SLN biopsy has been that early treat-
mentoftheregionalnodalbasincouldincreasetherisk
of in-transit disease. This concern has been laid to rest
by multiple recent compelling evidence-based stud-
ies
8–11, including the MSLT-1.
1 In one study of
approximately 3400 patients with melanoma treated
withWLEalone,WLEplusELND,orWLEplusSLN
biopsy, the incidence of in-transit disease was 4.9% in
the WLE-alone group and 4.5% in the WLE-plus-
SLN-biopsy group, and a multivariate analysis indi-
cated that predictors of in-transit disease included
SLN status, tumor thickness, and ulceration, but not
type of procedure performed.
9 In other words, in-
transitmetastasiswasrelatedtotumorbiology,notthe
type of surgical procedure. Moreover, recent results
from MSLT-I show no difference in the rate of in-
transit metastasis between patients in the WLE-alone
groupandthoseintheWLE-plus-SLN-biopsygroup.
1
Some groups have evaluated less invasive methods
of lymph node evaluation, such as ultrasound. SLN
biopsy is typically well tolerated, especially in com-
parison with ELND; it contributes little additional
morbidity to WLE.
12 However, at present, an experi-
enced sonographer is able to identify only those SLN
metastases that have reached a minimum diameter of
approximately 4 mm to 5 mm, which represents a
signiﬁcant burden of disease that itself is associated
with a relatively high rate of future distant disease.
Contrast this minimum threshold for detection to our
own institutional experience, in which the median
largest SLN metastatic focus was only 1 mm for pa-
tients who had a positive SLN biopsy between 2000
and 2003; fewer than one in ﬁve patients had a largest
SLNmetastaticfocus>4 mm.Suchlimitedsensitivity
indetectingSLNdiseasearguesagainsttheroutineuse
of sonography as the sole surveillance tool for early
detection of clinically occult regional nodal disease.
Even in the absence of a clear overall survival
advantage conferred by SLN biopsy, the routine use
of this approach is justiﬁed in patients with primary
melanoma at risk for regional metastases as it oﬀers
accurate staging information and enhanced regional
disease control with little additional morbidity be-
yond what is normally experienced with WLE. Fur-
thermore, the collective evidence from the MSLT-1,
previous reported ELND trials, and a large retro-
spective multicenter trial together support the view
that survival is improved for the subset of patients
with microscopic nodal disease. Until a primary tu-
mor marker or proﬁle is identiﬁed that is a more
reliable indicator of outcome and natural history,
SLN biopsy should continue to be oﬀered as a min-
imally invasive method of achieving accurate lymph
node staging, achieving durable regional disease
control, and optimizing the chance for cure in newly
diagnosed patients with stage I and II melanoma.
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